Tapasin is a facilitator, not an editor, of class I MHC peptide binding - PubMed (original) (raw)
Comparative Study
. 2003 Nov 15;171(10):5287-95.
doi: 10.4049/jimmunol.171.10.5287.
Affiliations
- PMID: 14607930
- DOI: 10.4049/jimmunol.171.10.5287
Comparative Study
Tapasin is a facilitator, not an editor, of class I MHC peptide binding
Angela L Zarling et al. J Immunol. 2003.
Abstract
Tapasin has been proposed to function as a peptide editor to displace lower affinity peptides and/or to favor the binding of high affinity peptides. Consistent with this, cell surface HLA-B8 molecules in tapasin-deficient cells were less stable and the peptide repertoire was substantially altered. However, the binding affinities of peptides expressed in the absence of tapasin were unexpectedly higher, not lower. The peptide repertoire from cells expressing soluble tapasin was similar in both appearance and affinity to that presented in the presence of full-length tapasin, but the HLA-B8 molecules showed altered cell surface stability characteristics. Similarly, the binding affinities of HLA-A*0201-associated peptides from tapasin(+) and tapasin(-) cells were equivalent, although steady state HLA-A*0201 cell surface expression was decreased and the molecules demonstrated reduced cell surface stability on tapasin(-) cells. These data are inconsistent with a role for tapasin as a peptide editor. Instead, we propose that tapasin acts as a peptide facilitator. In this role, it stabilizes the peptide-free conformation of class I MHC molecules in the endoplasmic reticulum and thus increases the number and variety of peptides bound to class I MHC. Full-length tapasin then confers additional stability on class I MHC molecules that are already associated with peptides.
Similar articles
- Qualitative and quantitative differences in peptides bound to HLA-B27 in the presence of mouse versus human tapasin define a role for tapasin as a size-dependent peptide editor.
Sesma L, Galocha B, Vázquez M, Purcell AW, Marcilla M, McCluskey J, López de Castro JA. Sesma L, et al. J Immunol. 2005 Jun 15;174(12):7833-44. doi: 10.4049/jimmunol.174.12.7833. J Immunol. 2005. PMID: 15944288 - Differential requirement for tapasin in the presentation of leader- and insulin-derived peptide antigens to Qa-1b-restricted CTLs.
Li L, Sullivan BA, Aldrich CJ, Soloski MJ, Forman J, Grandea AG 3rd, Jensen PE, Van Kaer L. Li L, et al. J Immunol. 2004 Sep 15;173(6):3707-15. doi: 10.4049/jimmunol.173.6.3707. J Immunol. 2004. PMID: 15356116 - A charged amino acid residue in the transmembrane/cytoplasmic region of tapasin influences MHC class I assembly and maturation.
Petersen JL, Hickman-Miller HD, McIlhaney MM, Vargas SE, Purcell AW, Hildebrand WH, Solheim JC. Petersen JL, et al. J Immunol. 2005 Jan 15;174(2):962-9. doi: 10.4049/jimmunol.174.2.962. J Immunol. 2005. PMID: 15634919 - Accessory proteins that control the assembly of MHC molecules with peptides.
Van Kaer L. Van Kaer L. Immunol Res. 2001;23(2-3):205-14. doi: 10.1385/IR:23:2-3:205. Immunol Res. 2001. PMID: 11444385 Review. - HLA-DM, HLA-DO and tapasin: functional similarities and differences.
Brocke P, Garbi N, Momburg F, Hämmerling GJ. Brocke P, et al. Curr Opin Immunol. 2002 Feb;14(1):22-9. doi: 10.1016/s0952-7915(01)00294-1. Curr Opin Immunol. 2002. PMID: 11790529 Review.
Cited by
- Dual role of the peptide-loading complex as proofreader and limiter of MHC-I presentation.
Brunnberg J, Barends M, Frühschulz S, Winter C, Battin C, de Wet B, Cole DK, Steinberger P, Tampé R. Brunnberg J, et al. Proc Natl Acad Sci U S A. 2024 May 28;121(22):e2321600121. doi: 10.1073/pnas.2321600121. Epub 2024 May 21. Proc Natl Acad Sci U S A. 2024. PMID: 38771881 Free PMC article. - Mass Spectrometric Profiling of HLA-B44 Peptidomes Provides Evidence for Tapasin-Mediated Tryptophan Editing.
Kaur A, Surnilla A, Zaitouna AJ, Mumphrey MB, Basrur V, Grigorova I, Cieslik M, Carrington M, Nesvizhskii AI, Raghavan M. Kaur A, et al. J Immunol. 2023 Nov 1;211(9):1298-1307. doi: 10.4049/jimmunol.2300232. J Immunol. 2023. PMID: 37737643 Free PMC article. - Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy.
Yang K, Halima A, Chan TA. Yang K, et al. Nat Rev Clin Oncol. 2023 Sep;20(9):604-623. doi: 10.1038/s41571-023-00789-4. Epub 2023 Jun 16. Nat Rev Clin Oncol. 2023. PMID: 37328642 Review. - In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.
Dervovic D, Malik AA, Chen ELY, Narimatsu M, Adler N, Afiuni-Zadeh S, Krenbek D, Martinez S, Tsai R, Boucher J, Berman JM, Teng K, Ayyaz A, Lü Y, Mbamalu G, Loganathan SK, Lee J, Zhang L, Guidos C, Wrana J, Valipour A, Roux PP, Reimand J, Jackson HW, Schramek D. Dervovic D, et al. Nat Commun. 2023 May 31;14(1):3150. doi: 10.1038/s41467-023-38841-7. Nat Commun. 2023. PMID: 37258521 Free PMC article. - Mass spectrometric profiling of HLA-B44 peptidomes provides evidence for tapasin-mediated tryptophan editing.
Kaur A, Surnilla A, Zaitouna AJ, Basrur V, Mumphrey MB, Grigorova I, Cieslik M, Carrington M, Nesvizhskii AI, Raghavan M. Kaur A, et al. bioRxiv [Preprint]. 2023 Feb 27:2023.02.26.530125. doi: 10.1101/2023.02.26.530125. bioRxiv. 2023. PMID: 36909546 Free PMC article. Updated. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials